M&A Deal Summary

Eilean Therapeutics Acquires Ness

On March 4, 2024, Eilean Therapeutics acquired life science company Ness

Acquisition Highlights
  • This is Eilean Therapeutics’ 1st transaction in the Life Science sector.
  • This is Eilean Therapeutics’ 1st transaction in Canada.
  • This is Eilean Therapeutics’ 1st transaction in Ontario.

M&A Deal Summary
Date 2024-03-04
Target Ness
Sector Life Science
Buyer(s) Eilean Therapeutics
Deal Type Add-on Acquisition

Target

Ness

Toronto, Ontario, Canada
Ness develops PTPN2 inhibitors providing an immuno-oncological therapy with an improved safety and tolerability profile.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Eilean Therapeutics

Dover, Delaware, United States
Category Company
Sector Life Science
DESCRIPTION

Eilean Therapeutics is a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies. Eilean is based in Dover, Delaware.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal